US FDA approved Dupixent that contains active pharmaceutical ingredient dupilumab for the treatment of atopic dermatitis also known as eczema. This drug is administered in the parenteral dosage form to treat eczema that is not responsive to topical therapy or severe kind of eczema.
Ezema or dermatitis is a group of skin disorders that occur due to autoimmune disease, allergic reaction, skin inflammation or infection. Some common manifestations of eczema are inflammation of epidermis, blistering, skin thickening, redness of skin, severe itching and burning sensation. Most commonly affected areas are hand, foot and arms but it might affect the whole body in some cases.
As far as etiology is concerned, many researchers believe that environmental allergens, genetic predisposition, immune system modulation and poor venous return act as triggering factors in pathogenesis of eczema but still the exact underlying cause is not yet fully known. Allergic dermatitis or eczema is most common form eczema that is common among all populations without regard to age and gender.
Dupixent/dupilumab is a monoclonal antibody used as immunotherapy. Pharmacologically, it has affinity to bind with sub-part of interleukin-4 receptor (IL-4Rα). It causes inhibition or modulation of IL-4Rα that plays important role in inflammatory pathway and release of inflammatory mediators. In such way Dupixent reduces inflammation and severity of disease.
Dupixent/dupilumab Side effects
According to According to data obtained from health authorities drug induced side effects were moderate to severe during clinical trails. Detail of these side effects are
- Hypersensitivity (anaphylaxis)
- Corneal Inflammation (keratitis)
- Scleral inflammation
- Pain at injection site
- Skin redness
- Blisters or cold sores
Dupixent/dupilumab Uses or Patient Information
There are number topical therapies available for eczema treatment but US FDA approved Dupixent as breakthrough therapy due to promising result in eczema patients. US FDA approved this drug for eczema that is less responsive to topical therapy or severe kind of eczema.